Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 324 articles:
HTML format



Single Articles


    May 2024
  1. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    PubMed     Abstract available


  2. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    PubMed    


  3. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    PubMed     Abstract available


  4. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
    Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
    Neurology. 2024;102:e209395.
    PubMed     Abstract available


  5. LIAO J, Lu Y, Lu Y, Huang Y, et al
    Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
    Neurology. 2024;102:e209302.
    PubMed     Abstract available


  6. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    PubMed     Abstract available


  7. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    PubMed     Abstract available


  8. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
    Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
    Neurology. 2024;102:e209297.
    PubMed     Abstract available


    April 2024
  9. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
    Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
    Neurology. 2024;102:e209282.
    PubMed     Abstract available


  10. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
    Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
    Neurology. 2024;102:e209284.
    PubMed    


  11. MOEHLMAN M, Kornbluh AB
    Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;102:e209259.
    PubMed    



  12. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    PubMed    


  13. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
    Pathologic Features of Anti-Ku Myositis.
    Neurology. 2024;102:e209268.
    PubMed     Abstract available


  14. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    PubMed     Abstract available


  15. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    PubMed     Abstract available


  16. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
    Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
    Neurology. 2024;102:e209245.
    PubMed    


  17. THAKOLWIBOON S, Dubey D
    Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
    Neurology. 2024;102:e209213.
    PubMed    


  18. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
    Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
    Neurology. 2024;102:e208101.
    PubMed     Abstract available


  19. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
    Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
    Neurology. 2024;102:e209257.
    PubMed    


  20. AGYEI P, Chen M, Guo Y, Perez CA, et al
    Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
    Neurology. 2024;102:e209187.
    PubMed     Abstract available


    March 2024
  21. YOUNG A, Johnston JL
    Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
    Neurology. 2024;102:e209260.
    PubMed     Abstract available


  22. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
    Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
    Neurology. 2024;102:e209130.
    PubMed     Abstract available


  23. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    PubMed    


  24. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    PubMed     Abstract available


  25. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    PubMed    


  26. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    PubMed     Abstract available



  27. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    PubMed    


  28. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    PubMed     Abstract available


  29. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    PubMed    


  30. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    PubMed     Abstract available


  31. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    PubMed     Abstract available


    February 2024
  32. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
    Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
    Neurology. 2024;102:e208019.
    PubMed     Abstract available


  33. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    PubMed     Abstract available


  34. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
    Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
    Neurology. 2024;102:e209153.
    PubMed    


  35. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    PubMed     Abstract available


  36. WU J, Guo K, Liu J
    Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;102:e208064.
    PubMed     Abstract available


  37. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    PubMed     Abstract available


  38. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
    Patient With Rigidity and Fasciculations.
    Neurology. 2024;102:e208110.
    PubMed     Abstract available


  39. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    PubMed     Abstract available


    January 2024
  40. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    PubMed     Abstract available


  41. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
    Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
    Neurology. 2024;102:e207937.
    PubMed     Abstract available


  42. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    PubMed     Abstract available


  43. HABIB AA, Sacks N, Cool C, Durgapal S, et al
    Hospitalizations and Mortality From Myasthenia Gravis.
    Neurology. 2024;102:e207863.
    PubMed     Abstract available


  44. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    PubMed     Abstract available


  45. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    PubMed     Abstract available


  46. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    PubMed     Abstract available


  47. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    PubMed     Abstract available


  48. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    PubMed     Abstract available


  49. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
    Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2024;102:e207965.
    PubMed     Abstract available


  50. ALKABIE S, Gray MT, Lau JC, Barra L, et al
    Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
    Neurology. 2024;102:e208018.
    PubMed     Abstract available


    December 2023
  51. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    PubMed     Abstract available


  52. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
    Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
    Neurology. 2023;101:e2585-e2588.
    PubMed     Abstract available


  53. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    PubMed     Abstract available


    November 2023
  54. LI X, Stitt D, Lanzino G, Giannini C, et al
    Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2023;101:979-980.
    PubMed    


    October 2023
  55. SRIVASTAVA I, Van Haren K
    Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
    PubMed    


  56. BOURDETTE D, Silbermann E
    What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
    PubMed    


  57. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
    Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
    PubMed     Abstract available


  58. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
    Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
    PubMed     Abstract available


  59. GUASP M, Dalmau J
    Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
    Neurology. 2023;101:656-660.
    PubMed     Abstract available


  60. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    PubMed     Abstract available


  61. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
    Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
    Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
    PubMed     Abstract available


    September 2023
  62. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    PubMed     Abstract available


  63. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    PubMed    


  64. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    PubMed     Abstract available


  65. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    PubMed     Abstract available


  66. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    PubMed     Abstract available


  67. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    PubMed    


    August 2023
  68. JACOBS BC
    [Correction] CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207874.
    PubMed    


  69. FANG CEH, Bokre D, Wong SH
    Clinical Characteristics Associated With Secondary Generalization in Ocular Myasthenia Gravis Patients: A Systematic Review and Meta-analysis.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207642.
    PubMed     Abstract available


  70. BSTEH G, Hegen H, Altmann P, Auer M, et al
    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
    Neurology. 2023;101:e784-e793.
    PubMed     Abstract available


  71. GRAVES JS
    Cell Specific Aging in Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
    PubMed    


  72. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
    Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
    PubMed     Abstract available


    July 2023
  73. BRAYO P, Serrano E, Thakkar RS, Osborne B, et al
    Pearls & Oy-sters: Syndrome of Inappropriate Antidiuretic Hormone Secretion Presenting as Neuromyelitis Optica Spectrum Disorder Flare.
    Neurology. 2023;101:e455-e458.
    PubMed     Abstract available


  74. HACOHEN Y, Tur C
    Treatment De-escalation in AQP4-Ab Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;101:153-154.
    PubMed    


  75. DEMUTH S, Collongues N, Audoin B, Ayrignac X, et al
    Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;101:e438-e450.
    PubMed     Abstract available


  76. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
    Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
    Neurology. 2023;101:e425-e437.
    PubMed     Abstract available


  77. QUINN C, Moulton K, Farwell M, Le W, et al
    Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
    PubMed     Abstract available


  78. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    PubMed     Abstract available


  79. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    PubMed     Abstract available


  80. LONGBRAKE E, Kalincik T
    Early Treatment for Multiple Sclerosis: Time Is Brain.
    Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
    PubMed    


  81. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
    Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
    PubMed     Abstract available


  82. HOSHINA Y, Wright MA, Warner JE, Richards T, et al
    Pearls & Oy-sters: ATX-FGF14 Mimicking Autoimmune Pathology.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207590.
    PubMed     Abstract available


  83. BENNETT JL
    Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
    PubMed    


  84. LEVIT E, Leon J, Lincoln MR
    Pearls & Oy-sters: Homozygous Complement Factor I Deficiency Presenting as Fulminant Relapsing Complement-Mediated CNS Vasculitis.
    Neurology. 2023;101:e220-e223.
    PubMed     Abstract available


  85. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
    Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
    PubMed     Abstract available


  86. BAARS AE, Van Doorn PA, Jacobs BC, Kuitwaard K, et al
    Author Response: SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
    Neurology. 2023;101:51.
    PubMed    


  87. HARTH CE
    Reader Response: SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
    Neurology. 2023;101:50-51.
    PubMed    


  88. TOOSY AT, Vidal-Jordana A
    Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
    PubMed    


    June 2023
  89. KOCH-HENRIKSEN N
    Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
    PubMed    


  90. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
    Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
    Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
    PubMed     Abstract available


  91. ROTSTEIN D, Schneider R
    A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
    PubMed    


  92. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
    Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
    PubMed     Abstract available


  93. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
    Polygenicity of Comorbid Depression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
    PubMed     Abstract available


    May 2023
  94. SUN H, Zhang S, Yu T, Zhou D, et al
    Teaching NeuroImage: Primary CNS Vasculitis Mimicking Intracranial Tumor.
    Neurology. 2023;100:1072-1073.
    PubMed    


  95. BRENNER J, Mariotto S, Bastiaansen AEM, Paunovic M, et al
    Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:e2204-e2213.
    PubMed     Abstract available


  96. KUNCHOK A, Dalmau J
    Can Neurofilament Light Chain Be Utilized as a Biomarker of Disease Severity, Activity, and Outcomes in Anti-NMDA Receptor Encephalitis?
    Neurology. 2023;100:991-992.
    PubMed    


  97. SCHEEL M, Pruss H, Finke C
    Reader Response: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:887.
    PubMed    


  98. GANESH A, Galetta S
    Editors' Note: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:886.
    PubMed    


  99. BUDHRAM A, Mirian A, Sharma M
    Reader Response: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:886-887.
    PubMed    


    April 2023
  100. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
    Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
    Neurology. 2023;100:e1776-e1786.
    PubMed     Abstract available



  101. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
    Neurology. 2023 Apr 25:10.1212/WNL.0000000000207433.
    PubMed    


  102. AL-HAKEM H, Doets AY, Stino AM, Zivkovic SA, et al
    Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome.
    Neurology. 2023 Apr 19:10.1212/WNL.0000000000207282.
    PubMed     Abstract available


  103. SEJVAR J
    Cerebrospinal Fluid In Guillain-Barre Syndrome: It's a Matter of Timing.
    Neurology. 2023 Apr 19:10.1212/WNL.0000000000207203.
    PubMed    


  104. GUPTILL JT, Benatar M, Granit V, Habib AA, et al
    Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials.
    Neurology. 2023 Apr 19:10.1212/WNL.0000000000207278.
    PubMed     Abstract available


  105. LEAVITT VM
    The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
    PubMed    


  106. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
    Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
    PubMed     Abstract available


    March 2023
  107. KIM HJ, Palace J
    Should We test for IgG Antibodies Against MOG in Both Serum and CSF in Patients With Suspected MOGAD?
    Neurology. 2023;100:497-498.
    PubMed    


  108. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
    Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
    Neurology. 2023;100:e1095-e1108.
    PubMed     Abstract available


    February 2023
  109. PIZZOLATO UMETON R, Waltz M, Aaen GS, Benson L, et al
    Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;100:e985-e994.
    PubMed     Abstract available


  110. LALLA R, Narasimhan R, Abdalkader M, Virmani D, et al
    Teaching NeuroImage: Imaging and Pathologic Findings in SARS-CoV-2-Related Acute Demyelinating Encephalomyelitis.
    Neurology. 2023 Feb 16:10.1212/WNL.0000000000207095.
    PubMed    


  111. LEWIS A, Galetta S
    Editors' Note: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2023;100:310-311.
    PubMed    


  112. LEWIS A, Galetta S
    Editors' Note: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2023;100:309.
    PubMed    


  113. CORNBLATH W, Eggenberger E
    Reader Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2023;100:311.
    PubMed    


  114. SECHI E, Defazio G, Erre GL, Solla P, et al
    Author Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2023;100:311-312.
    PubMed    


  115. CAO S, Zhu Y, Xue Q, Xia M, et al
    Reader Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2023;100:309-310.
    PubMed    


  116. CHEN J, Shah S
    Author Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2023;100:310.
    PubMed    


    January 2023
  117. LEONHARD SE, van der Eijk AA, Willison HJ, Jacobs BC, et al
    Author Response: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2023;100:264.
    PubMed    


  118. DEBNATH M, Nagappa M
    Reader Response: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2023;100:263-264.
    PubMed    


  119. GANESH A, Galetta S
    Editors' Note: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2023;100:263.
    PubMed    


  120. PATIL SA, Grossman S, Kenney R, Balcer LJ, et al
    Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture.
    Neurology. 2023;100:244-253.
    PubMed     Abstract available



  121. Pathologic Features of Anti-Mi-2 Dermatomyositis.
    Neurology. 2023 Jan 24:10.1212/WNL.0000000000201611.
    PubMed    


  122. CACCIAGUERRA L, Morris P, Tobin WO, Chen JJ, et al
    Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023 Jan 23:10.1212/WNL.0000000000206820.
    PubMed     Abstract available


  123. HORTON MK, Robinson SC, Shao X, Quach H, et al
    A Cross-Trait, Mendelian Randomization Study to Investigate Whether Migraine Is a Risk Factor for Multiple Sclerosis.
    Neurology. 2023 Jan 11:10.1212/WNL.0000000000206791.
    PubMed     Abstract available


    December 2022
  124. DONCEL-MORIANO CUBERO A, Espigol G, Renu A
    Teaching NeuroImage: Bilateral Internal Carotid Artery Stenosis Due to Aggressive Giant Cell Arteritis.
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206823.
    PubMed    


  125. BORDEA E, Hunter RM
    Excess Treatment Costs of Multiple Sclerosis: What Can We Learn From Longitudinal Population-Based Data?
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206804.
    PubMed    


  126. GAVOILLE A, Rollot F, Casey R, Debouverie M, et al
    Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206774.
    PubMed     Abstract available


  127. BERGSLAND N, Dwyer MG, Jakimovski D, Tavazzi E, et al
    Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000201608.
    PubMed     Abstract available


  128. BOFFA G, Signori A, Massacesi L, Mariottini A, et al
    Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206750.
    PubMed     Abstract available


  129. MULLER J, Noteboom S, Granziera C, Schoonheim MM, et al
    Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206806.
    PubMed    


  130. MULLER-JENSEN L, Kriedemann H, Anvari K, Huehnchen P, et al
    Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Neurology. 2022 Dec 20:10.1212/WNL.0000000000206743.
    PubMed    


    November 2022
  131. KHAKBAN A, Llorian ER, Michaux KD, Patten SB, et al
    Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study From 2001 to 2020 in British Columbia, Canada.
    Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
    PubMed     Abstract available


  132. BARRERAS P, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
    Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Neurology. 2022;99:e2504-e2516.
    PubMed     Abstract available


  133. ZIEMSSEN T
    Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:868.
    PubMed    


  134. PARNETTI L, Gaetani L
    Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:869.
    PubMed    


  135. DEERHAKE ME, Giarraputo J, Gupta M, Eckstein C, et al
    Journal Club: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:854-857.
    PubMed    


  136. LEWIS A, Galetta S
    Editors' Note: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818.
    PubMed    


  137. BEBO BF
    Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:819.
    PubMed    


  138. VARGAS WS
    Reader Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818-819.
    PubMed    


    October 2022
  139. LI L, Avina-Zubieta JA, Bernstein CN, Kaplan GG, et al
    Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor Alpha in Four Canadian Provinces: A Population-Based Study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201472.
    PubMed     Abstract available



  140. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201391.
    PubMed    


  141. STRIJBIS EMM, Koch MW
    TNF Alfa Blockers and the Risk of Multiple Sclerosis.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201629.
    PubMed    


  142. DOBSON R, Bove R
    In Vitro Fertilization and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022;99:737-738.
    PubMed    


  143. BRIL V, Szczudlik A, Vaitkus A, Rozsa C, et al
    A Randomized, Double-Blind, Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
    Neurology. 2022 Oct 21. pii: WNL.0000000000201501.
    PubMed     Abstract available


  144. DUBESSY AL, Stankoff B, Arnulf I
    Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:727.
    PubMed    


  145. SIEGLER JE, Galetta S
    Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726.
    PubMed    


  146. SPARASCI D, Zecca C, Gobbi C, Manconi M, et al
    Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726-727.
    PubMed    


  147. SNETSELAAR L, Cheek JJ, Fox SS, Healy HS, et al
    Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201371.
    PubMed     Abstract available


  148. SPAIN R, Piccio L, Langer-Gould AM
    The Role of Diet in Multiple Sclerosis: Food for Thought.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201565.
    PubMed    


  149. MURPHY OC, Calabresi PA, Gold DR
    Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201452.
    PubMed    


  150. GANESH A, Galetta S
    Editors' Note: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630.
    PubMed    


  151. BARRO C
    Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630-631.
    PubMed    


  152. LEPPERT D, Kropshofer H, Haring D, Dahlke F, et al
    Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:631.
    PubMed    


  153. CORTESE R, Carrasco FP, Tur C, Bianchi A, et al
    Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Neurology. 2022 Oct 3. pii: WNL.0000000000201465.
    PubMed     Abstract available


    September 2022
  154. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    PubMed     Abstract available


  155. BAARS AE, Kuitwaard K, de Koning LC, Luijten LWG, et al
    SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201376.
    PubMed     Abstract available


  156. ALLEN JA
    SARS-CoV-2 Vaccination and Autoimmune Neuropathies: Rebalancing the Risk.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201366.
    PubMed    


  157. COTE-OROZCO JE, Velez-Tirado N
    Teaching NeuroImage: Hypothalamic Involvement in Neuromyelitis Optica Spectrum Disorder in a Child.
    Neurology. 2022;99:535-536.
    PubMed    


  158. GANESH A, Galetta S
    Editors' Note: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:489.
    PubMed    


  159. VALE S
    Reader Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:491.
    PubMed    


  160. GUASP M, Dalmau J
    Author Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:490.
    PubMed    


  161. JEANTIN L, Plu I, Amador MDM, Maillart E, et al
    Pearls & Oy-sters: Spinal Cord Candidiasis Linked to CARD9 Deficiency Masquerading as a Longitudinally Extensive Transverse Myelitis.
    Neurology. 2022;99:475-479.
    PubMed     Abstract available


  162. CAROTENUTO A, Valsasina P, Schoonheim MM, Geurts JJ, et al
    Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201264.
    PubMed     Abstract available


    August 2022
  163. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
    Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
    PubMed    


  164. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
    Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
    PubMed     Abstract available


  165. VILLOSLADA P, Llufriu S
    Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201223.
    PubMed    


  166. HWANG S, Garcia-Dominguez MA, Fitzgerald KC, Saylor DR, et al
    Association of Multiple Sclerosis Prevalence With Sociodemographic, Health Systems, and Lifestyle Factors on a National and Regional Level.
    Neurology. 2022 Aug 24. pii: WNL.0000000000200962.
    PubMed     Abstract available


  167. LOPEZ-JIMENEZ A, Gutierrez-Gutierrez G, Guerra-Hiraldo JD, Kurtis MM, et al
    Teaching Video NeuroImage: Hung-Up Reflex in Stiff Limb Syndrome.
    Neurology. 2022;99:356.
    PubMed    


  168. SHAH SS, Morris P, Buciuc M, Tajfirouz D, et al
    Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2022;99:e851-e857.
    PubMed     Abstract available


  169. BRENTON JN, Florenzo B, Koshiya H, Min S, et al
    Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2022 Aug 19. pii: WNL.0000000000201098.
    PubMed     Abstract available


  170. LEONHARD SE, van der Eijk AA, Andersen H, Antonini G, et al
    An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2022 Aug 18. pii: WNL.0000000000200885.
    PubMed     Abstract available


  171. ROOS I, Malpas C, Leray E, Casey R, et al
    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022 Aug 17. pii: WNL.0000000000201029.
    PubMed     Abstract available


  172. MCLAREN JR, Mitchell MK, Al-Maadid FM, Staley KJ, et al
    Clinical Reasoning: An 8-Year-Old With Acute Onset Ataxia.
    Neurology. 2022;99:305-310.
    PubMed     Abstract available


  173. DOBSON R, Bove R
    IVF and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201242.
    PubMed    


  174. MAINGUY M, Tillaut H, Degremont A, Le Page E, et al
    Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201027.
    PubMed     Abstract available


  175. O'MAHONY J, Salter A, Ciftci B, Fox RJ, et al
    Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.
    Neurology. 2022 Aug 10. pii: WNL.0000000000200931.
    PubMed     Abstract available


  176. SECHI E, Gallus E, Solla P, Puggioni D, et al
    Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2022;99:256-257.
    PubMed    


  177. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
    Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
    Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
    PubMed     Abstract available


  178. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    PubMed     Abstract available


    July 2022
  179. KUANG SY, Li Y, Yang SL, Han X, et al
    Child Neurology: Aicardi-Goutieres Syndrome Presenting as Recurrent Ischemic Stroke.
    Neurology. 2022 Jul 8. pii: WNL.0000000000200952.
    PubMed     Abstract available


    June 2022
  180. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
    The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
    Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
    PubMed     Abstract available


  181. TOOSY AT, Eshaghi A
    Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
    Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
    PubMed    


  182. FREEDMAN MS, Pozzilli C, Havrdova EK, Lemle A, et al
    Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
    Neurology. 2022 Jun 6. pii: WNL.0000000000200606.
    PubMed     Abstract available


    May 2022
  183. SOTIRCHOS ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
    Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Neurology. 2022 May 26. pii: WNL.0000000000200778.
    PubMed     Abstract available


  184. GRAVES J
    Identifying Multiple Sclerosis Activity: Do the Eyes Have It?
    Neurology. 2022 May 26. pii: WNL.0000000000200903.
    PubMed    


  185. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022;98:737-738.
    PubMed    


  186. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022;98:e1818-e1827.
    PubMed     Abstract available


  187. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022;98:e1798-e1809.
    PubMed     Abstract available


    April 2022
  188. WU Q, Zhao CW, Dai S
    Teaching Video NeuroImage: Generalized Reflex Myoclonus in Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome.
    Neurology. 2022 Apr 29. pii: WNL.0000000000200733.
    PubMed    


  189. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022 Apr 28. pii: WNL.0000000000200366.
    PubMed    


  190. HAMILTON R, Ciccarelli O
    Multiple Sclerosis Incidence in Black Patients: It's Time to Do Away With a Racial Medical Myth.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200309.
    PubMed    


  191. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200151.
    PubMed     Abstract available


  192. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200163.
    PubMed     Abstract available


  193. ROTSTEIN D, Solomon JM, Sormani MP, Montalban X, et al
    Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Neurology. 2022 Apr 26. pii: WNL.0000000000200549.
    PubMed     Abstract available


  194. OKAI AF, Howard AM, Williams MJ, Brink JD, et al
    Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200791.
    PubMed     Abstract available


  195. PORTACCIO E, Bellinvia A, Razzolini L, Pasto L, et al
    Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
    Neurology. 2022;98:e1626-e1636.
    PubMed     Abstract available


  196. SWART G, Balgobind S, Chan C, Fulham M, et al
    Spinal Cord Presentation of Biopsy-Proven PET-Positive Giant Cell Arteritis.
    Neurology. 2022 Apr 15. pii: WNL.0000000000200749.
    PubMed     Abstract available


  197. BEBO B, Cintina I, LaRocca N, Ritter L, et al
    Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200150.
    PubMed     Abstract available


  198. OSTKAMP P, Schwab N
    Effects of Latitude and Sunlight on Multiple Sclerosis Severity: Two Peas in a Pod?
    Neurology. 2022 Apr 11. pii: WNL.0000000000200105.
    PubMed    


  199. VITKOVA M, Diouf I, Malpas C, Horakova D, et al
    Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
    Neurology. 2022 Apr 11. pii: WNL.0000000000200545.
    PubMed     Abstract available


  200. GUASP M, Martin-Aguilar L, Sabater L, Bioque M, et al
    Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;98:e1489-e1498.
    PubMed     Abstract available


  201. LEPPERT D, Kropshofer H, Haring DAA, Dahlke F, et al
    Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200258.
    PubMed     Abstract available


    March 2022
  202. GALLAY L, Fermon C, Lessard L, Weiss-Gayet M, et al
    Involvement of Type-I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200271.
    PubMed     Abstract available


  203. PINAL-FERNANDEZ I, Greenberg SA
    Type I Interferons in Dermatomyositis Myoblasts: Toxic Effect and a Potential Autocrine Loop.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200679.
    PubMed    


  204. BOURDETTE D, Sormani MP
    Thinking Anew: Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200597.
    PubMed    


  205. LI V, Leurent B, Barkhof F, Braisher M, et al
    Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200604.
    PubMed     Abstract available


  206. MOLIMARD A, Gitiaux C, Barnerias C, Audic F, et al
    Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200288.
    PubMed     Abstract available


  207. BRIDEL C, Killestein J, Teunissen C
    Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:471.
    PubMed    


  208. KROPSHOFER H, Haring DA, Kappos L, Leppert D, et al
    Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470-471.
    PubMed    


  209. LEWIS A, Galetta S
    Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470.
    PubMed    


  210. HUMMERT MW, Schoppe LM, Bellmann-Strobl J, Siebert N, et al
    Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE(NMO) Study.
    Neurology. 2022;98:e1184-e1196.
    PubMed     Abstract available


  211. SIMMONS SB, Ontaneda D
    Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?
    Neurology. 2022 Mar 11. pii: WNL.0000000000200230.
    PubMed    


  212. AZZOLINI F, Farina A, Gastaldi M, Barilaro A, et al
    Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP-Astrocytopathy.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200291.
    PubMed    


  213. CALVI A, Carrasco FP, Tur C, Chard DT, et al
    Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200144.
    PubMed     Abstract available


  214. ZENG YH, Zhao M, Guo XX, Wang N, et al
    Cutaneous Lesions as a Clue to the Etiology of Extensive Intracranial Calcifications: Aicardi-Goutieres Syndrome.
    Neurology. 2022;98:417-418.
    PubMed    


  215. LEVISON LS, Thomsen RW, Sindrup SH, Andersen H, et al
    Association Between Incident Cancer and Guillain-Barre Syndrome Development: A Nationwide Case-Control Study.
    Neurology. 2022 Mar 2. pii: WNL.0000000000200015.
    PubMed     Abstract available


  216. HAMILTON RH, Ciccarelli O
    Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials.
    Neurology. 2022;98:345-346.
    PubMed    


    February 2022
  217. MARZOUGHI S, Marulanda L, Ngo D, Chen T, et al
    Pearls & Oy-sters: Delayed Diagnosis of Acute Motor Axonal Neuropathy With Cardiac Arrest.
    Neurology. 2022;98:336-339.
    PubMed    


  218. LIE IA, Weeda MM, Mattiesing RM, Mol MAE, et al
    Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200006.
    PubMed     Abstract available


  219. MCELWEE DECKER B, Thibault D, Davis KA, Willis AW, et al
    Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.
    Neurology. 2022 Feb 15. pii: WNL.0000000000200007.
    PubMed     Abstract available


  220. HACOHEN Y, Ciccarelli O
    New Evidence for EBV Infection as a Cause of Multiple Sclerosis.
    Neurology. 2022 Feb 10. pii: WNL.0000000000200243.
    PubMed    


  221. MAMMEN AL
    Inclusion Body Myositis: An Autoimmune or Myodegenerative Disease?
    Neurology. 2022 Feb 7. pii: WNL.0000000000200188.
    PubMed    


  222. TORTORELLA C, Aiello A, Gasperini C, Agrati C, et al
    Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Neurology. 2022;98:e541-e554.
    PubMed     Abstract available


    January 2022
  223. ONUORAH HM, Charron O, Meltzer E, Montague A, et al
    Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
    Neurology. 2022 Jan 19. pii: WNL.0000000000013230.
    PubMed     Abstract available


  224. CUTTER GR, Koch MW
    Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
    Neurology. 2022;98:12-13.
    PubMed    


  225. FILIPPI M, Preziosa P, Meani A, Dalla Costa G, et al
    Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
    Neurology. 2022;98:e1-e14.
    PubMed     Abstract available


    December 2021
  226. DOETS AY, Lingsma HF, Walgaard C, Islam B, et al
    Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013139.
    PubMed     Abstract available


  227. MIRZA AI, Zhu F, Knox N, Forbes JD, et al
    Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013245.
    PubMed     Abstract available


  228. COSTA AF, Rodriguez A, Martinez P, Blanco DCM, et al
    Teaching Video NeuroImage: Uncommon Neuro-ophthalmic Finding in a Patient With Miller Fisher Syndrome and Past SARS-CoV-2 Infection.
    Neurology. 2021;97:e2431-e2432.
    PubMed    


  229. SHELLY S, Klein CJ, Dyck PJB, Paul P, et al
    Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.
    Neurology. 2021;97:e2392-e2403.
    PubMed     Abstract available


  230. SEBASTIAN P, Cherbuin N, Barcellos LF, Roalstad S, et al
    Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013045.
    PubMed     Abstract available


  231. GRAVES JS, Killestein J
    Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013166.
    PubMed    


  232. TANBOON J, Inoue M, Saito Y, Tachimori H, et al
    Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
    Neurology. 2021 Dec 6. pii: WNL.0000000000013176.
    PubMed     Abstract available


  233. NOWAK RJ, Coffey CS, Goldstein JM, Dimachkie MM, et al
    Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
    Neurology. 2021 Dec 2. pii: WNL.0000000000013121.
    PubMed     Abstract available


    November 2021
  234. NEUPERT DG, Rathke KM, Mikati MA
    Teaching Video NeuroImage: Hereditary Hyperekplexia Mimicking Tonic Seizures in an Infant.
    Neurology. 2021;97:e2248-e2249.
    PubMed     Abstract available


  235. TENCER J, Yum SW
    Teaching NeuroImage: Basal Ganglia T1 Hyperintensity and SWI Signal Diabetic Striatopathy in an 18-Year-Old Man With Type 1 Diabetes Mellitus.
    Neurology. 2021;97:e2148-e2149.
    PubMed    


  236. DUMONCEAU AG, Ameli R, Rogemond V, Ruiz A, et al
    Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.
    Neurology. 2021 Nov 19. pii: WNL.0000000000013087.
    PubMed     Abstract available


    October 2021

  237. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
    Neurology. 2021 Oct 29. pii: WNL.0000000000013021.
    PubMed    


  238. AMATO A
    Author Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
    Neurology. 2021;97:841-842.
    PubMed    


  239. WILLER J
    Reader Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
    Neurology. 2021;97:841.
    PubMed    


  240. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
    Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Neurology. 2021;97:e1641-e1652.
    PubMed     Abstract available


  241. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
    Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
    PubMed     Abstract available


  242. KALINCIK T, Tremlett H, Ascherio A
    High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
    PubMed    


  243. AGHAJAN Y, Mitchell RN, Bhattacharyya S, Hsu TY, et al
    Teaching NeuroImage: Bilateral Middle Cerebellar Peduncle Stroke in Giant Cell Arteritis.
    Neurology. 2021 Oct 19. pii: WNL.0000000000012953.
    PubMed    


  244. JANDRIC D, Lipp I, Paling D, Rog D, et al
    Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
    PubMed     Abstract available


  245. SANCHEZ CV, Theel E, Binnicker M, Toledano M, et al
    Autoimmune Encephalitis Post-SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.
    Neurology. 2021 Oct 11. pii: WNL.0000000000012931.
    PubMed     Abstract available


  246. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    PubMed     Abstract available


  247. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
    PubMed    


  248. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    PubMed     Abstract available


  249. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
    PubMed    


  250. VRENKEN H, Jenkinson M, Pham D, Guttmann CRG, et al
    Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012884.
    PubMed     Abstract available


    September 2021
  251. ZHAO-FLEMING HH, Valencia Sanchez C, Sechi E, Inbarasu J, et al
    CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Neurology. 2021;97:e1351-e1358.
    PubMed     Abstract available


  252. MERLO D, Stankovich J, Bai C, Kalincik T, et al
    Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
    PubMed     Abstract available


  253. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
    PubMed     Abstract available


  254. TOBIN O
    Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
    PubMed    


  255. CAMELO-FILHO AE, Estephan EP, Heise CO, Zanoteli E, et al
    Teaching Video NeuroImage: Reflex Facilitation in Lambert-Eaton Myasthenic Syndrome.
    Neurology. 2021;97:e1168-e1169.
    PubMed    


  256. MILLER JW
    Inflammation As A Target For Epilepsy Therapy: The Case of Natalizumab.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012768.
    PubMed    


  257. GOLDSCHMIDT C, Fox RJ
    Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
    PubMed    


  258. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
    Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
    PubMed     Abstract available


  259. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
    Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
    PubMed     Abstract available


  260. RADCLIFFE C, Potnis K, Peng TJ, DeCroce-Movson E, et al
    Teaching NeuroImage: Papilledema and Pachymeningitis: An Atypical Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2021;97:e1060-e1061.
    PubMed    


  261. YEH EA, Bourdette D, Wiendl H
    Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
    PubMed    


  262. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
    Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
    PubMed     Abstract available


  263. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
    Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
    PubMed     Abstract available


  264. SALTER A
    Assessment of Biological Interactions Between MS Status and Depression for Mortality.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
    PubMed    


    August 2021
  265. RICE J, Xiang XM
    Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2021;97:e972-e974.
    PubMed    


  266. DOBSON R, Salter A
    Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
    Neurology. 2021;97:407-408.
    PubMed    


  267. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
    PubMed     Abstract available


  268. PETERSSON M, Feresiadou A, Jons D, Ilinca A, et al
    Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012604.
    PubMed     Abstract available


  269. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
    Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
    PubMed     Abstract available


  270. FREY J, Kramer J, Castellani R, Sriwastava S, et al
    Clinical Reasoning: A 47-Year-Old With Headache, Vertigo, and Double Vision.
    Neurology. 2021;97:e535-e539.
    PubMed    


  271. STRUPP M, Frenzel C, Goldschagg N, Halmagyi GM, et al
    Teaching Video NeuroImage: One Bedside Test, 2 Clinical Signs: One Vestibular, the Other Ocular Motor.
    Neurology. 2021;97:e541-e542.
    PubMed    


    July 2021
  272. KARCESKI S
    Myasthenia Gravis: Which Type of Surgery Is Best?
    Neurology. 2021;97:e433-e435.
    PubMed    


  273. CHEN T
    Clinical Reasoning: A 68-Year-Old Man With Proximal Weakness and Seizures.
    Neurology. 2021;97:e423-e428.
    PubMed    


  274. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    PubMed     Abstract available


  275. RASMINSKY M
    GCA Squared.
    Neurology. 2021;97:90-91.
    PubMed    


  276. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
    Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
    Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
    PubMed     Abstract available


  277. LISAK RP
    [Editorial] At the Junction Where It Happens: Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia Gravis [re: M/S #2020/169756].
    Neurology. 2021 Jul 7. pii: WNL.0000000000012471.
    PubMed    


  278. YU Z, Zhang M, Jing H, Chen P, et al
    Characterization of LRP4/Agrin Antibodies From a Patient with Myasthenia Gravis.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012463.
    PubMed     Abstract available


  279. HACOHEN Y, Kerr W, Waters P
    Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
    Neurology. 2021;97:12-13.
    PubMed    


  280. AKAISHI T, Takahashi T, Misu T, Kaneko K, et al
    Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2021;97:e1-e12.
    PubMed     Abstract available


  281. GUASP M, Gine-Serven E, Maudes E, Rosa-Justicia M, et al
    Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis.
    Neurology. 2021;97:e61-e75.
    PubMed     Abstract available


    June 2021
  282. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    PubMed     Abstract available


  283. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    PubMed     Abstract available


  284. MYERS KA
    Author Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
    Neurology. 2021;96:1105.
    PubMed    


  285. FUJIMORI J, Nakashima I
    Reader Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
    Neurology. 2021;96:1104-1105.
    PubMed    


  286. VILLACIEROS-ALVAREZ J, Ordas CM, Torres-Gaona G, Diez-Barrio A, et al
    Teaching Video NeuroImages: Anti-IgLON5 Disease: A Long-Course Presentation With a Response to Immunotherapy.
    Neurology. 2021;96:e2901-e2902.
    PubMed    


  287. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
    Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
    PubMed     Abstract available


  288. PREZIOSA P, Schoonheim MM
    Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
    PubMed    


  289. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
    Secondary Progressive Multiple Sclerosis: New Insights.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
    PubMed     Abstract available


  290. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
    Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
    PubMed     Abstract available


    May 2021
  291. SAN MARTIN AH, Cuadrado CA, Arbizu MG, Rabano-Suarez P, et al
    Autoimmune Septin-5 Disease Presenting as Spinocerebellar Ataxia and Nystagmus.
    Neurology. 2021 May 24. pii: WNL.0000000000012240.
    PubMed    


  292. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
    Neurology. 2021 May 19. pii: WNL.0000000000012224.
    PubMed     Abstract available


  293. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 May 19. pii: WNL.0000000000012127.
    PubMed     Abstract available


  294. JOLLIFFE EA, Guo Y, Hardy TA, Morris PP, et al
    Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis.
    Neurology. 2021 May 19. pii: WNL.0000000000012230.
    PubMed     Abstract available


  295. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    PubMed    


  296. DAY GS, Yarbrough MY, Kortvelyessy P, Pruss H, et al
    Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis.
    Neurology. 2021;96:e2546-e2557.
    PubMed     Abstract available


  297. TITULAER MJ, Day GS
    Autoimmune Encephalitis in First Episode Psychoses: All Smoke and No Fire?
    Neurology. 2021 May 12. pii: WNL.0000000000012195.
    PubMed    


  298. GIANNOCCARO MP, Liguori R
    Author Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
    Neurology. 2021;96:918-919.
    PubMed    


  299. SILVESTRI N
    Reader Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
    Neurology. 2021;96:918.
    PubMed    


  300. NERSESJAN V, McWilliam O, Krarup LH, Kondziella D, et al
    Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review.
    Neurology. 2021 May 5. pii: WNL.0000000000012122.
    PubMed     Abstract available



  301. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 May 4. pii: WNL.0000000000011825.
    PubMed    


  302. SOLIS-PAZMINO P, Baiu I, Lincango-Naranjo E, Trope W, et al
    Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia Gravis: A Meta-analysis.
    Neurology. 2021 May 4. pii: WNL.0000000000012153.
    PubMed     Abstract available


  303. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    PubMed    


  304. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    PubMed     Abstract available


  305. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed    


  306. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed    


  307. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    PubMed    


    April 2021
  308. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
    Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
    PubMed     Abstract available


  309. ZOUVELOU V, Daponte A
    Teaching Video NeuroImages: Resolution of Ptosis After Forceful Eye Closure: Bedside Diagnosis of Myasthenia Gravis.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012100.
    PubMed    


  310. LEAVITT VM, Dobson R, Svennigsson A
    Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
    PubMed    


  311. SHELLY S, Mills JR, Dubey D, McKeon A, et al
    Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012050.
    PubMed     Abstract available


  312. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
    Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
    PubMed    


  313. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
    Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
    PubMed     Abstract available


  314. SOLOMON AJ, Ascherio A
    Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
    PubMed    



  315. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
    PubMed    


  316. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
    Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
    PubMed     Abstract available


  317. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
    Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
    PubMed     Abstract available


  318. SHELLY S, Shouman K, Paul P, Engelstad J, et al
    Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus.
    Neurology. 2021;96:e2078-e2089.
    PubMed     Abstract available


  319. NISHIDA H, Kohyama K, Kumada S, Takanashi JI, et al
    Evaluation of the Diagnostic Criteria for Anti-NMDA Receptor Encephalitis in Japanese Children.
    Neurology. 2021;96:e2070-e2077.
    PubMed     Abstract available


  320. COLLONGUES N, Alves Do Rego C, Bourre B, Biotti D, et al
    Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.
    Neurology. 2021;96:e2006-e2015.
    PubMed     Abstract available


  321. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
    Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
    PubMed     Abstract available


  322. BOURDETTE D, Killestein J
    Quelling Public Fears about Guillain-Barre Syndrome and COVID-19 Vaccination.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011882.
    PubMed    


  323. MARQUEZ LOZA AM, Holroyd KB, Johnson SA, Pilgrim DM, et al
    Guillain- Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011881.
    PubMed    


  324. ALLEN JA, Pasnoor M, Dimachkie MM, Ajroud-Driss S, et al
    Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.
    Neurology. 2021;96:e1876-e1886.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.